Immunostimulatory monoclonal antibodies for cancer therapy

Ignacio Melero, Sandra Hervas-Stubbs, Martin Glennie, Drew M. Pardoll, Lieping Chen

Research output: Contribution to journalReview articlepeer-review

459 Scopus citations


Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results.

Original languageEnglish (US)
Pages (from-to)95-106
Number of pages12
JournalNature Reviews Cancer
Issue number2
StatePublished - Feb 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunostimulatory monoclonal antibodies for cancer therapy'. Together they form a unique fingerprint.

Cite this